| Features: |
| Dipyridamole is a medication primarily used for its antiplatelet and vasodilatory effects.(cardiovascular)
Dipyridamole is primarily known as a phosphodiesterase inhibitor and anti‐platelet agent. Mechanism: Dipyridamole inhibits phosphodiesterases (PDEs), enzymes that break down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cancer Relevance: Increased cyclic nucleotide levels can affect cell proliferation, apoptosis, and differentiation. Elevated cAMP, for example, may contribute to growth arrest or modify signaling cascades in certain cancer cells. • Dipyridamole has been observed in some studies to exert antioxidant effects. • There is evidence—albeit less definitive in some cases—that dipyridamole might influence mitochondrial function, potentially altering the balance between ROS production and detoxification. • By stabilizing mitochondrial membranes or affecting mitochondrial signaling pathways, dipyridamole could reduce the likelihood of excessive ROS generation. Current literature does not provide strong evidence that dipyridamole directly inhibits the mevalonate pathway?? A) Nucleoside Salvage Blockade -Tumors often rely on nucleoside salvage under stress. -Dipyridamole blocks nucleoside uptake → replication stress and DNA synthesis pressure, especially when de novo synthesis is compromised. B) Metabolic Stress & Redox Effects -Interferes with PPP/NADPH support in certain contexts. -Can sensitize cells to oxidative and metabolic stress, tipping stressed tumors toward death. C) Adenosine Signaling Modulation -By altering extracellular/intracellular adenosine handling, dipyridamole can modify immune and stress signaling in the tumor microenvironment (context-dependent). -Chemo-sensitizer (adjunct) Yes (experimental) -Chemopreventive candidate Yes (preclinical/observational) |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 4986- | ATV, | Dipy, | The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer |
| - | Review, | Var, | NA |
| 4984- | Dipy, | ATV, | Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop |
| - | in-vitro, | AML, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:293 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid